These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24408120)

  • 21. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B; Gan L; Liu B; Yuan W; Shi M; Peng A; Wang L; Chen X; Liu T; Zhang S; Wang S; Gao Q; Wang B; Zheng H; Liu C; Luo Y; Ye H; Lin H; Li Y; He Q; Zheng F; Luo P; Long G; Lu W; Li K; Yang J; Liu YC; Zhang Z; Li X; Zhang W; Zuo L
    Nephrol Dial Transplant; 2024 Sep; 39(10):1649-1661. PubMed ID: 38453435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
    Li L; Zheng X; Deng J; Zhou J; Ou J; Hong T
    Ren Fail; 2022 Dec; 44(1):1112-1122. PubMed ID: 35912897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
    Yokoyama K; Hirakata H; Akiba T; Sawada K; Kumagai Y
    Am J Nephrol; 2012; 36(5):478-87. PubMed ID: 23147696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Iron, aluminum, and lanthanum-based drugs for treatment of hyperphosphatemia].
    Matsumura K
    Yakugaku Zasshi; 2015; 135(4):545-9. PubMed ID: 25832833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
    Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J
    Nephron; 2020; 144(9):428-439. PubMed ID: 32585670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
    Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
    McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
    Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.
    Yokoyama K; Fukagawa M; Akiba T; Nakayama M; Ito K; Hanaki K; Wolf M; Hirakata H
    Sci Rep; 2019 Jun; 9(1):8877. PubMed ID: 31222044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.